✦ LIBER ✦

Rituximab in Indolent Lymphomas

✍ Scribed by Tarek Sousou; Jonathan Friedberg

Book ID: 117822175
Publisher: Elsevier Science
Year: 2010
Tongue: English
Weight: 489 KB
Volume: 47
Category: Article
ISSN: 1532-8686
DOI: 10.1053/j.seminhematol.2010.01.003

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Rituximab maintenance in indolent lympho

Rituximab maintenance in indolent lymphoma: Indications and controversies

✍ Marinus H.J. van Oers 📂 Article 📅 2007 🏛 Current Science Inc. 🌐 English ⚖ 260 KB

Combined lenalidomide, low-dose dexameth

Combined lenalidomide, low-dose dexamethasone, and rituximab achieves durable responses in rituximab-resistant indolent and mantle cell lymphomas

✍ Ahmadi, Tahamtan; Chong, Elise A.; Gordon, Amanda; Aqui, Nicole A.; Nasta, Sunit 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 250 KB

Rituximab (Mabthera™, rituxan™) in patie

Rituximab (Mabthera™, rituxan™) in patients with recurrent indolent lymphoma

✍ J. Walewski; E. Kraszewska; O. Mioduszewska; J. Romejko-Jarosińska; A. Hellmann; 📂 Article 📅 2001 🏛 Springer US 🌐 English ⚖ 83 KB

Factors Predicting the Response to Ritux

Factors Predicting the Response to Rituximab in Indolent Lymphoma

✍ Lee, David 📂 Article 📅 2003 🏛 CIG Media Group, LP. 🌐 English ⚖ 113 KB

‘Indolent’ mature B-cell lymphomas

✍ Finbarr E. Cotter 📂 Article 📅 2009 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 91 KB

Advances in the treatment of indolent ly

Advances in the treatment of indolent lymphomas

✍ Tomasz Wróbel; Grzegorz Mazur 📂 Article 📅 2004 🏛 Wielkopolskie Centrum Onkologii 🌐 Polish ⚖ 103 KB

Non-Hodgkin's lymphomas (nHL) are a heterogenous group of lymphoid malignancies with a different pattern of behaviour and response to treatment. In Europe and North America mainly B-cell lymphomas (86%) are observed. Indolent lymphomas are lymphoproliferative diseases with a relatively good prognosi